Pozen, Teva Bury Hatchet Over Treximet
Pozen Inc. has reached a settlement with Teva Pharmaceuticals USA Inc. in a patent suit over Teva's plans for a generic version of the migraine treatment Treximet, marketed in the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article